These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 33940309)

  • 1. Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis.
    Moll M; Zon RL; Sylvester KW; Rimsans J; Chen EC; Ghosh AJ; Abston E; Kim A; Rutherford H; Mitre X; Hakim A; Connell NT; Battinelli E; Fredenburgh LE; Baron RM; Hobbs BD; Cho MH; Mittleman MA; Woolley AE; Connors JM
    Thromb Res; 2021 Jul; 203():57-60. PubMed ID: 33940309
    [No Abstract]   [Full Text] [Related]  

  • 2. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
    Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
    Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
    Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
    JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin resistance in COVID-19 patients in the intensive care unit.
    White D; MacDonald S; Bull T; Hayman M; de Monteverde-Robb R; Sapsford D; Lavinio A; Varley J; Johnston A; Besser M; Thomas W
    J Thromb Thrombolysis; 2020 Aug; 50(2):287-291. PubMed ID: 32445064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
    INSPIRATION-S Investigators
    BMJ; 2022 Jan; 376():e068407. PubMed ID: 34996756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis.
    Ionescu F; Jaiyesimi I; Petrescu I; Lawler PR; Castillo E; Munoz-Maldonado Y; Imam Z; Narasimhan M; Abbas AE; Konde A; Nair GB
    Eur J Haematol; 2021 Feb; 106(2):165-174. PubMed ID: 33043484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An observational study of intermediate- or high-dose thromboprophylaxis for critically ill COVID-19 patients.
    Jonmarker S; Litorell J; Dahlberg M; Stackelberg O; Everhov ÅH; Söderberg M; Rubenson-Wahlin R; Günther M; Mårtensson J; Hollenberg J; Joelsson-Alm E; Cronhjort M
    Acta Anaesthesiol Scand; 2022 Mar; 66(3):365-374. PubMed ID: 34875111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of non-COVID-19 critically ill patients during the COVID-19 pandemic : A retrospective propensity score-matched analysis.
    Bologheanu R; Maleczek M; Laxar D; Kimberger O
    Wien Klin Wochenschr; 2021 Sep; 133(17-18):942-950. PubMed ID: 33909109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study.
    Al Harthi AF; Aljuhani O; Korayem GB; Altebainawi AF; Alenezi RS; Al Harbi S; Gramish J; Kensara R; Hafidh A; Al Enazi H; Alawad A; Alotaibi R; Alshehri A; Alhuthaili O; Vishwakarma R; Bin Saleh K; Alsulaiman T; Alqahtani RA; Hussain S; Almazrou S; Al Sulaiman K
    J Intensive Care Med; 2022 Sep; 37(9):1238-1249. PubMed ID: 35450493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin and SARS-CoV-2: Multiple Pathophysiological Links.
    Di Micco P; Imbalzano E; Russo V; Attena E; Mandaliti V; Orlando L; Lombardi M; Di Micco G; Camporese G; Annunziata S; Piccinocchi G; Pacelli W; Del Guercio M
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
    Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC
    Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department.
    Marchioni C; Esposito G; Calci M; Bais B; Colussi G
    BMC Emerg Med; 2022 Jun; 22(1):107. PubMed ID: 35698054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.
    Tremblay D; van Gerwen M; Alsen M; Thibaud S; Kessler A; Venugopal S; Makki I; Qin Q; Dharmapuri S; Jun T; Bhalla S; Berwick S; Feld J; Mascarenhas J; Troy K; Cromwell C; Dunn A; Oh WK; Naymagon L
    Blood; 2020 Jul; 136(1):144-147. PubMed ID: 32462179
    [No Abstract]   [Full Text] [Related]  

  • 15. Thromboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study.
    Bocci MG; Maviglia R; Consalvo LM; Grieco DL; Montini L; Mercurio G; Nardi G; Pisapia L; Cutuli SL; Biasucci DG; Gori C; Rosenkranz R; De Candia E; Carelli S; Natalini D; Antonelli M; Franceschi F
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12466-12479. PubMed ID: 33336766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
    ; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
    JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: A propensity score-matched cohort study.
    Spiegelenberg JP; van Gelder MMHJ; Maas ML; Hovens MMC; Esselink A; Dofferhoff ASM; Janssen R; van de Maat J; Janssen N; Blaauw M; Hassing RJ; van Apeldoorn M; Kerckhoffs A; Veerman K; Hoogerwerf J; Kramers C; Leentjens J
    Br J Clin Pharmacol; 2021 Dec; 87(12):4839-4847. PubMed ID: 33899226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
    Bikdeli B; Talasaz AH; Rashidi F; Bakhshandeh H; Rafiee F; Rezaeifar P; Baghizadeh E; Matin S; Jamalkhani S; Tahamtan O; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Khalili H; Yadollahzadeh M; Riahi T; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Amin A; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Dobesh PP; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
    Thromb Haemost; 2022 Jan; 122(1):131-141. PubMed ID: 33865239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Another new application of heparin in COVID-19: more than anticoagulation and antiviral.
    Yu X
    J Investig Med; 2021 Aug; 69(6):1258. PubMed ID: 34112704
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study.
    Denas G; Gennaro N; Ferroni E; Fedeli U; Lorenzoni G; Gregori D; Iliceto S; Pengo V
    Int J Cardiol; 2021 Apr; 329():266-269. PubMed ID: 33309764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.